Market Research Logo

Icagen Inc - Strategic SWOT Analysis Review

Icagen Inc - Strategic SWOT Analysis Review

- provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – GlobalData’s summarization of the company’s business strategy.
  • SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
Highlights

Icagen Inc (Icagen) (formerly known as XRpro Sciences, Inc.) is a biopharmaceutical company which develops drug candidates to unmet medical need and commercial opportunity. The company discovers drug for clinical stage across multiple therapeutics and ion class channel classes. The company provides technologies including high throughput fluorescence, manual and automated electrophysiology, and radiotracer flux. It offers screening services to pharmaceutical sector, including the use of proprietary x-ray fluorescence technology which is marketed as XRpro. It also delivers contract research services such as ion channel and transporter screening, assay development, cell line generation and custom assay services. The company has collaborations with Pfizer, Inc. Icagen is headquartered at Durham in North Carolina, the US.

Icagen Inc Key Recent Developments

May 24,2017: Icagen to Showcase its Integrated Drug Discovery Platform at BIO International
Jan 30,2017: Icagen announces distribution agreement with On Target for advancing early drug discovery in Japanese market
Aug 25,2016: Icagen Appoints Chris Mathes as Chief Commercial Officer
May 16,2016: Icagen Issued U.S. Patent Covering Diagnostic and Discovery Applications of its Proprietary XRpro X-Ray Fluorescence Technology
Feb 22,2016: Aptuit and Icagen Agree to Strategic Alliance

Reasons to Buy
  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.


Section 1 - About the Company 5
Icagen Inc - Key Facts 5
Icagen Inc - Key Employees 6
Icagen Inc - Key Employee Biographies 7
Icagen Inc - Major Products and Services 8
Icagen Inc - History 9
Icagen Inc - Company Statement 10
Icagen Inc - Locations And Subsidiaries 13
Head Office 13
Section 2 – Company Analysis 14
Icagen Inc - Business Description 14
Icagen Inc - SWOT Analysis 15
SWOT Analysis - Overview 15
Icagen Inc - Strengths 15
Icagen Inc - Weaknesses 16
Icagen Inc - Opportunities 17
Icagen Inc - Threats 18
Icagen Inc - Key Competitors 19
Section 3 – Company’s Lifesciences Financial Deals and Alliances 20
Icagen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 20
Icagen Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 21
Icagen Inc, Recent Deals Summary 22
Section 4 – Company’s Recent Developments 23
May 24, 2017: Icagen to Showcase its Integrated Drug Discovery Platform at BIO International 23
Jan 30, 2017: Icagen announces distribution agreement with On Target for advancing early drug discovery in Japanese market 24
Aug 25, 2016: Icagen Appoints Chris Mathes as Chief Commercial Officer 25
May 16, 2016: Icagen Issued U.S. Patent Covering Diagnostic and Discovery Applications of its Proprietary XRpro X-Ray Fluorescence Technology 26
Feb 22, 2016: Aptuit and Icagen Agree to Strategic Alliance 27
Jan 21, 2016: Icagen to Showcase Ion Channel and Transporter Drug Discovery and Development Expertise at SLAS 2016 28
Section 5 – Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29
List of Tables
Icagen Inc, Key Facts 5
Icagen Inc, Key Employees 6
Icagen Inc, Key Employee Biographies 7
Icagen Inc, Major Products and Services 8
Icagen Inc, History 9
Icagen Inc, Key Competitors 19
Icagen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 20
Icagen Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 21
Icagen Inc, Recent Deals Summary 22
List of Figures
Icagen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 20
Icagen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 21

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report